2021
NAFLD-related HCC
Banini BA, Sanyal AJ. NAFLD-related HCC. Advances In Cancer Research 2021, 149: 143-169. PMID: 33579423, DOI: 10.1016/bs.acr.2020.11.001.ChaptersConceptsNonalcoholic fatty liver diseaseHepatocellular carcinomaType 2 diabetes mellitusFatty liver diseaseNumber of patientsDiabetes mellitusMetabolic syndromeLiver diseaseCurrent evidenceMain molecular mechanismsMetabolic perturbationsTwo- toUnites StatesMolecular mechanismsMellitusObesityPatientsCarcinomaGlobal increaseSyndromeDiseaseIncidenceHepatocarcinogenesis
2019
The use of cell free DNA in the diagnosis of HCC
Banini BA, Sanyal AJ. The use of cell free DNA in the diagnosis of HCC. Hepatoma Research 2019, 2019: 34. PMID: 31673629, PMCID: PMC6822275, DOI: 10.20517/2394-5079.2019.30.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsDiagnosis of HCCHepatocellular carcinomaNon-invasive biomarkersCommon malignant tumorPotential clinical utilityCell-free nucleic acidsTypes of cancerCell-free DNALiquid biopsy analysisAnalysis of bloodLiver biopsyPeripheral bloodTumor recurrenceMalignant tumorsProstate cancerEarly diagnosisClinical utilityBiopsy analysisAdvanced stageHigh mortalityTreatment monitoringLiquid biopsyDiagnosisBody fluidsBiopsyUpdates on Chronic HBV: Current Challenges and Future Goals
Lee HM, Banini BA. Updates on Chronic HBV: Current Challenges and Future Goals. Current Treatment Options In Gastroenterology 2019, 17: 271-291. PMID: 31077059, DOI: 10.1007/s11938-019-00236-3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsTenofovir alafenamide fumarateGlobal public health problemPublic health problemChronic HBVHepatocellular carcinomaLiver failureCurative treatmentLiver diseaseAntiviral therapyClinical trialsHealth problemsLaboratory safety parametersNew treatment recommendationsAdvanced liver diseaseComplications of cirrhosisCurrent antiviral therapiesEarly phase studiesLong-term useNucleotide analog drugsHBV reactivationLiver decompensationFunctional cureTherapeutic armamentariumTreatment recommendationsImproved outcomes
2017
Transcriptional Induction of Periostin by a Sulfatase 2–TGFβ1–SMAD Signaling Axis Mediates Tumor Angiogenesis in Hepatocellular Carcinoma
Chen G, Nakamura I, Dhanasekaran R, Iguchi E, Tolosa EJ, Romecin PA, Vera RE, Almada LL, Miamen AG, Chaiteerakij R, Zhou M, Asiedu MK, Moser CD, Han S, Hu C, Banini BA, Oseini AM, Chen Y, Fang Y, Yang D, Shaleh HM, Wang S, Wu D, Song T, Lee JS, Thorgeirsson SS, Chevet E, Shah VH, Fernandez-Zapico ME, Roberts LR. Transcriptional Induction of Periostin by a Sulfatase 2–TGFβ1–SMAD Signaling Axis Mediates Tumor Angiogenesis in Hepatocellular Carcinoma. Cancer Research 2017, 77: 632-645. PMID: 27872089, PMCID: PMC5429157, DOI: 10.1158/0008-5472.can-15-2556.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBiomarkers, TumorBlotting, WesternCarcinoma, HepatocellularCell Adhesion MoleculesChromatin ImmunoprecipitationEnzyme-Linked Immunosorbent AssayGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansImmunohistochemistryKaplan-Meier EstimateLiver NeoplasmsMiceMice, KnockoutNeovascularization, PathologicOligonucleotide Array Sequence AnalysisReal-Time Polymerase Chain ReactionSignal TransductionSmad ProteinsSulfatasesSulfotransferasesTransforming Growth Factor beta1ConceptsHepatocellular carcinomaSulfatase 2Protein periostinMicrovascular densityHCC cellsExtracellular matrix protein periostinTGFβ1/Smad pathwayMetastatic hepatocellular carcinomaLower microvascular densityPoor patient survivalWild-type miceClinical HCC specimensHuman HCC cellsPatient survivalPOSTN levelsAntiangiogenic approachesKO miceRational drug developmentParacrine fashionNumerous tumorsHCC angiogenesisTumor growthEndothelial proliferationTumor angiogenesisHCC specimens
2015
Hepatocellular Carcinoma
Banini B, Roberts L. Hepatocellular Carcinoma. 2015, 207-218. DOI: 10.1007/978-3-319-13614-1_22.ChaptersHepatocellular carcinomaHepatitis C virus-associated cirrhosisCoexistence of HCCHepatitis B virus infectionPathophysiology of HCCB virus infectionCancer-related deathHCC incidencePrimary etiologyCurrent therapiesCommon causeVirus infectionPrognostic assessmentNew casesCarcinomaHigh rateDate summaryDeathSaharan AfricaComplex diseasesCirrhosisPatientsPathophysiologyEtiologyTherapy